Miyagoe-Suzuki Y, Takeda S. Skeletal muscle generated from induced pluripotent stem cells - induction and application. World J Stem Cells 2017; 9(6): 89-97 [PMID: 28717411 DOI: 10.4252/wjsc.v9.i6.89]
Corresponding Author of This Article
Yuko Miyagoe-Suzuki, MD, PhD, Section Chief, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan. miyagoe@ncnp.go.jp
Research Domain of This Article
Cell Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Jun 26, 2017; 9(6): 89-97 Published online Jun 26, 2017. doi: 10.4252/wjsc.v9.i6.89
Skeletal muscle generated from induced pluripotent stem cells - induction and application
Yuko Miyagoe-Suzuki, Shin’ichi Takeda
Yuko Miyagoe-Suzuki, Shin’ichi Takeda, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan
Author contributions: Miyagoe-Suzuki Y primarily wrote the manuscript; Takeda S supervised the writing.
Supported by The Program for Intractable Diseases Research utilizing Disease-specific iPS cells (Japan Agency for Medical Research and Development: AMED), No. 15652069; Projects for Technological Development (K1), from the Research Center Network for Realization of Regenerative Medicine (AMED); Intramural Research Grants for Neurological and Psychiatric Disorders of NCNP, No. 27-7; Grant-in-Aid for Scientific Research (C) (Japan Society for the Promotion of Science), No. 16744921.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yuko Miyagoe-Suzuki, MD, PhD, Section Chief, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan. miyagoe@ncnp.go.jp
Telephone: +81-42-3461720 Fax: +81-42-3461750
Received: January 29, 2017 Peer-review started: February 13, 2017 First decision: March 27, 2017 Revised: May 9, 2017 Accepted: May 18, 2017 Article in press: May 19, 2017 Published online: June 26, 2017 Processing time: 147 Days and 13 Hours
Abstract
Human induced pluripotent stem cells (hiPS cells or hiPSCs) can be derived from cells of patients with severe muscle disease. If skeletal muscle induced from patient-iPSCs shows disease-specific phenotypes, it can be useful for studying the disease pathogenesis and for drug development. On the other hand, human iPSCs from healthy donors or hereditary muscle disease-iPSCs whose genomes are edited to express normal protein are expected to be a cell source for cell therapy. Several protocols for the derivation of skeletal muscle from human iPSCs have been reported to allow the development of efficient treatments for devastating muscle diseases. In 2017, the focus of research is shifting to another stage: (1) the establishment of mature myofibers that are suitable for study of the pathogenesis of muscle disease; (2) setting up a high-throughput drug screening system; and (3) the preparation of highly regenerative, non-oncogenic cells in large quantities for cell transplantation, etc.
Core tip: Skeletal muscle cells induced from patient induced pluripotent stem cells (iPSCs) are useful for the study of pathogenesis and drug development. The derivation of mature myofibers is required for disease modeling. On the other hand, human iPSCs from healthy donors are likely to be a cell source for cell therapy. For safe cell transplantation, non-oncogenic cells are needed.
